Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed
Advanced Ovarian Cancer
FIGO Stage III-IV
BRCA Mutation
Complete Response
Partial Response
First Line Platinum Chemotherapy

Interventions

DRUG: Olaparib 300mg tablets

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]